New Glioma Test Provides Answers during Surgical Procedures
By LabMedica International staff writers Posted on 13 Aug 2018 |
A new diagnostic test detects certain mutations in glioma tumors during brain surgery and identifies those sensitive to metabolic chemotherapeutic agents.
A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise about 30% of all brain tumors and central nervous system tumors, and 80% of all malignant brain tumors. Lower-grade gliomas are often characterized by mutations in the metabolism-related genes IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2). Patients with glioma carrying mutations in either IDH1 or IDH2 have a relatively favorable survival, compared with patients with glioma with wild-type IDH1/2 genes.
Treating brain cancer and preventing recurrence has proven to be difficult, as the blood-brain barrier represents a considerable hurdle. To get around the blood brain barrier issue, investigators at Brigham and Women's Hospital (Boston, MA, USA), Massachusetts General Hospital (Boston, USA) and the Massachusetts Institute of Technology (Cambridge, MA, USA) hypothesized that application of metabolism-altering therapeutics at the surgical margin would improve tumor control and minimize toxicity. To facilitate this process, they developed an intraoperative diagnostic assay to identify IDH mutations.
The rapid multiplexed genotyping tool they developed was used to analyze previously collected patient samples. Results demonstrated that the assay could detect mutations within 27 minutes. For 75 of the 87 clinically annotated brain tumor specimens tested, the assay detected the presence of one or more mutations.
"The first and perhaps most important step in treatment of brain tumors is the initial operation, or craniotomy, which obtains tissue to make the diagnosis, and, for lower grade lesions, provides a therapeutic benefit from removal of the tumor mass," said senior author Dr. Daniel Cahill, associate professor of neurosurgery at Massachusetts General Hospital. "Prior studies from our group, and others, have shown that aggressive surgery provides a substantial survival benefit for patients with lower-grade gliomas. We sought to build upon this surgical scenario, attempting to further prolong survival for these patients."
The glioma diagnostic test was described in the August 6, 2018, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.
Related Links:
Brigham and Women's Hospital
Massachusetts General Hospital
Massachusetts Institute of Technology
A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise about 30% of all brain tumors and central nervous system tumors, and 80% of all malignant brain tumors. Lower-grade gliomas are often characterized by mutations in the metabolism-related genes IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2). Patients with glioma carrying mutations in either IDH1 or IDH2 have a relatively favorable survival, compared with patients with glioma with wild-type IDH1/2 genes.
Treating brain cancer and preventing recurrence has proven to be difficult, as the blood-brain barrier represents a considerable hurdle. To get around the blood brain barrier issue, investigators at Brigham and Women's Hospital (Boston, MA, USA), Massachusetts General Hospital (Boston, USA) and the Massachusetts Institute of Technology (Cambridge, MA, USA) hypothesized that application of metabolism-altering therapeutics at the surgical margin would improve tumor control and minimize toxicity. To facilitate this process, they developed an intraoperative diagnostic assay to identify IDH mutations.
The rapid multiplexed genotyping tool they developed was used to analyze previously collected patient samples. Results demonstrated that the assay could detect mutations within 27 minutes. For 75 of the 87 clinically annotated brain tumor specimens tested, the assay detected the presence of one or more mutations.
"The first and perhaps most important step in treatment of brain tumors is the initial operation, or craniotomy, which obtains tissue to make the diagnosis, and, for lower grade lesions, provides a therapeutic benefit from removal of the tumor mass," said senior author Dr. Daniel Cahill, associate professor of neurosurgery at Massachusetts General Hospital. "Prior studies from our group, and others, have shown that aggressive surgery provides a substantial survival benefit for patients with lower-grade gliomas. We sought to build upon this surgical scenario, attempting to further prolong survival for these patients."
The glioma diagnostic test was described in the August 6, 2018, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.
Related Links:
Brigham and Women's Hospital
Massachusetts General Hospital
Massachusetts Institute of Technology
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer